Boehm Marcus 的 Form 4/A 修正申報
修正Vyant Bio, Inc.（VYNT），2021/7/1 申報
- 申報編號
- 0001493152-21-015911
- 申報時間
- 2021/7/1
- 交易日
- 2021/3/30-6/30
- 申報延遲
- 93 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/4/1
這份申報列了 7 筆非衍生性交易。公開市場買進合計 $3.72 萬。交易後 93 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Boehm MarcusCIK 0001850698 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/3/30 | Common Stock, $0.0001 par value | J其他取得 | +93,786 | –F1 | – | 93,786 | 直接 | |
| 2021/5/5 | Common Stock, $0.0001 par value | G贈與處分 | −78,263 | $0.00 | $0 | 15,253 | 直接 | |
| 2021/5/5 | Common Stock, $0.0001 par value | G贈與取得 | +78,263 | $0.00 | $0 | 78,263 | 間接 | |
| 2021/5/10 | Common Stock, $0.0001 par value | G贈與處分 | −15,523 | $0.00 | $0 | 0 | 直接 | |
| 2021/5/10 | Common Stock, $0.0001 par value | G贈與取得 | +15,523 | $0.00 | $0 | 93,786 | 間接 | |
| 2021/5/28 | Common Stock, $0.0001 par value | P買進取得 | +5,000 | $3.68 | +$18,400 | 98,786 | 間接 | |
| 2021/6/30 | Common Stock, $0.0001 par value | P買進取得 | +5,000 | $3.76F4 | +$18,800 | 103,786 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person under the Boehm Family Trust, Marcus & Kimberley Boehm Trustees on May 24, 2021.
- F3
Shares were previously reported as being directly held by reporting person.
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.8099 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
表 I 有 1 筆交易的價格引用這則附註。
備註
This amended Form 4 is being filed to correct (i) the number of shares issued pursuant to the merger on March 30, 2021, (ii) reporting person's indirect purchase of shares (via a trust) on May 28, 2021 and (iii) the disclosure of shares previously owned directly that were transferred to a trust reported on the Form 4 filed July 1, 2021.